Developer docs
API playgroundTry for free, no card

Search company profiles

Intervacc

Full company profile

uuid000aouc

Namestring
Intervacc
Legal namestring
Intervacc AB (publ)
Websiteurl
intervacc.se
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Intervacc AB (publ) is a Swedish biotechnology company listed on Nasdaq First North Growth Market (ticker: IVACC) that develops vaccines based on recombinant fusion protein technology for animal health applications. The company's core technology platform originated from research at Karolinska Institutet and the Swedish University of Agricultural Sciences (SLU), generating broad immune responses by targeting multiple virulence pathways of complex bacterial pathogens. Its flagship commercial product, Strangvac®, is a recombinant subunit vaccine against equine strangles (Streptococcus equi) approved in the EU, UK, Iceland, Norway, and Liechtenstein, providing over 90% protection following booster dose and uniquely offering DIVA (Differentiating Infected from Vaccinated Animals) capability that enables continued disease surveillance. The pipeline includes Piggivac® (INV274), a pig vaccine against Streptococcus suis that became the first globally to demonstrate statistically significant protection against serotypes ST1 and ST16 via maternal immunity, and INV412, a mastitis vaccine candidate for dairy cattle.

The company operates a hybrid distribution model: direct sales through its wholly-owned Nordvacc Läkemedel subsidiary (which has sold more than 200 million vaccine doses and holds distribution rights to 25 products across 8 Scandinavian and Baltic countries) for Scandinavia, and an exclusive distribution agreement with Dechra Pharmaceuticals PLC covering the rest of Europe (extended through April 2028). 2025 net sales were SEK 20.087 million, up 70% year-over-year, and the company is pursuing US regulatory approval with clinical safety studies initiated in December 2025. Beyond Strangvac and Piggivac, Intervacc operates Mybac-Vettech Laboratoriet for clinical microbiological analyses and is funded through a mix of equity (including a SEK 193 million rights issue in February 2025 that brought HealthCap IX Investments AB as a ~26% shareholder), EU grants (Eurostars-2/3), and Swedish innovation agency (Vinnova) grants.

Revenue is generated primarily from vaccine product sales (one-time purchase model through veterinary channels), with strategic positioning that emphasizes antimicrobial resistance reduction, scientific engagement via Key Opinion Leader networks, and awareness campaigns such as Strangles Awareness Week. The company is led by CEO Carl-Johan Dalsgaard (appointed February 2026, previously AstraZeneca) with Andrew Waller as CSO, Jan Persson as CFO, and Anna-Carin Lagerlöf as Director of Sales & Marketing, supported by Board Chair Emil Billbäck (appointed May 2026).

Short descriptiontext

Intervacc AB is a Swedish animal health biotech developing recombinant fusion protein vaccines, led by its flagship equine strangles vaccine Strangvac® (approved in 16+ European markets) and the pipeline-stage Piggivac® pig vaccine. It serves equine veterinarians and owners across Europe via direct sales (Nordvacc) and Dechra distribution, and is pursuing US regulatory entry.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
animal health vaccines, recombinant protein vaccines, veterinary pharmaceuticals, equine strangles vaccine, livestock vaccine development
Industry4 codes
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAIAEAH
Veterinary Vaccines
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Animal Health Vaccines
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Vaccine Product Sales
TypeOne Time License
Description

Revenue generated from sales of Strangvac vaccine for horses, sold directly in Scandinavia and through distribution partner Dechra across Europe. Net sales of SEK 20,087 thousand in 2025, up 70% from SEK 11,787 thousand in 2024.

intervacc.se
2Distribution Rights and Sales
TypeOne Time License
Description

Nordvacc subsidiary sells vaccines and pharmaceuticals across Scandinavia and Baltic countries with distribution rights to 25 products in 8 countries.

intervacc.se
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Intervacc develops and commercializes vaccines based on recombinant fusion proteins for animal health, with flagship product Strangvac® protecting horses against strangles (Streptococcus equi) and pipeline product Piggivac® targeting Streptococcus suis in pigs. The company sells Strangvac directly in Scandinavia and through Dechra Pharmaceuticals across Europe, while expanding its vaccine pipeline to address mastitis in dairy cattle.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 90% protection following booster vaccination against strangles
+3 more records
Product overview1 text field

Intervacc is a Swedish animal health group developing vaccines based on recombinant protein fusion technology for animals. The company's core product portfolio includes Strangvac®, an approved equine strangles vaccine registered in 16 European markets; Piggivac®, a pig vaccine against Streptococcus suis in advanced development; and two additional vaccine candidates (INV274 and INV412). Through subsidiaries Nordvacc Läkemedel (sales/distribution) and Mybac-Vettech Laboratoriet (analyses), Intervacc combines in-house vaccine development with established commercial infrastructure across European markets.

Product and service4 records
1Strangvac®
CategoryAnimal Health Vaccines
Description

A recombinant fusion protein vaccine against equine strangles (caused by Streptococcus equi), approved for sale and marketing in the EU, UK, Iceland, Norway, and Liechtenstein. Administered intramuscularly, it provides over 90% protection following booster dose and is the only strangles vaccine that permits diagnosis of exposed or infected horses.

2Piggivac®
CategoryAnimal Health Vaccines
Description

A subunit vaccine against Streptococcus suis infections in pigs, based on Intervacc's recombinant fusion protein platform. Administered to pregnant sows intramuscularly, transferring maternal immunity to piglets. Demonstrated statistically significant protection against virulent serotypes ST1 (serotype 2) and ST16 (serotype 9). No approved S. suis vaccines currently exist for pigs.

3Nordvacc Läkemedel (Distribution Services)
CategoryVeterinary Pharmaceutical Distribution
Description

A wholly-owned subsidiary of Intervacc operating as a sales and distribution organization with over 30 years of experience, having sold more than 200 million vaccine doses on the European animal health market. Handles distribution of Intervacc's products in Scandinavia and holds distribution rights to multiple products across 8 countries.

4Mybac-Vettech Laboratoriet (Microbiological Analyses)
CategoryVeterinary Diagnostic Services
Description

A subsidiary of Nordvacc performing clinical microbiological analyses, supporting diagnostic and analytical service capabilities.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Contract research organization specializing in animal health in Edinburgh, UK. Collaborating on Streptococcus suis vaccine (INV274/Piggivac) development including challenge studies and pivotal registration studies. Project co-funded by Eurostars 3 program.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-13
Description

Five-year distribution agreement (original April 2021, extended by 2 years from April 2026) for Strangvac vaccine in Europe excluding Scandinavia, Iceland, and Baltic countries. Dechra has launched Strangvac in 14 countries including UK, France, Germany, Spain, Portugal, Ireland, Poland, Slovenia, and Italy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-17
Description

Collaboration with Testa Center in Uppsala, Sweden for scale-up manufacturing of Streptococcus suis vaccine component. Project involves optimizing biopharmaceutical production processes with Vinnova funding of 800,000 SEK.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-11
Description

Multi-year contract for development of innovative animal health vaccines using recombinant proteins. Research collaboration provides foundation for Intervacc's vaccine platform technology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-07-09
Description

Manufacturing partner in Pamplona, Spain for large-scale commercial production of drug substances in Strangvac vaccine. Technology transfer and validation batch production completed for registration.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-07-09
Description

Provider of final formulation, vial filling, packaging, and final release of finished Strangvac product in Spain.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2014-03-24
Description

Wholly-owned subsidiary acquired in 2014 providing established distribution network in Scandinavia and Baltic countries. Has sold more than 150 million vaccine doses and holds distribution rights to 25 products in 8 countries. Also owns Mybac-Vettech performing clinical microbiological analyses.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Independent French animal health company with a strong vaccine portfolio across livestock, equine, and companion animals, plus a meaningful direct-sales presence in Europe. Closely comparable as a mid-sized independent animal vaccine specialist with European roots and international ambitions.

TypeBroad incumbent
Description

Independent French animal health company with a strong veterinary biologics and pharmaceutical portfolio, including equine and livestock products. Comparable as a mid-sized European independent animal health specialist with similar geographic and end-market overlap to Intervacc.

TypeBroad incumbent
Description

Major independent global animal health player headquartered in France, especially strong in poultry and swine vaccines. Relevant peer for the swine (Piggivac/INV274) side of Intervacc's portfolio and as a benchmark for independent vaccine R&D organizations competing against Big Pharma incumbents.

TypeBroad incumbent
Description

Specialty veterinary pharmaceuticals company (acquired by EQT in 2025) with strong European and North American equine/small animal footprint. Dechra is Intervacc's distribution partner for Strangvac in Europe and is directly comparable as a specialty vet pharma commercial channel.

TypeBroad incumbent
Description

Animal health and nutrition company with a meaningful vaccine and anti-infective business serving livestock and poultry. Comparable as a public pure-play animal health company whose stock-based valuation benchmark is helpful in sizing Intervacc's potential enterprise value trajectory.

TypeBroad incumbent
Description

The animal health division of Merck/MSD, offering vaccines, anti-infectives, and parasiticides globally. Operates the broadest portfolio of licensed veterinary biological products across species and is a key competitor and benchmark for any animal vaccine developer targeting livestock or equine markets.

TypeBroad incumbent
Description

World's largest pure-play animal health company, offering a broad portfolio of vaccines, parasiticides, and diagnostics across livestock and companion animals. Comparable as a manufacturer of veterinary biologics, including equine and livestock vaccines, with established global commercial scale that dwarfs Intervacc's current footprint.

TypeEmerging player
Description

German veterinary biologics contract manufacturer and vaccine developer with strong expertise in bacterial vaccines across species. Comparable as a specialized European veterinary biologics platform — relevant for both competitive technology benchmarking and as a potential manufacturing counterpart for Intervacc-type recombinant subunit products.

TypeBroad incumbent
Description

Global pure-play animal health company with significant vaccine franchises in livestock and companion animals (acquired Bayer Animal Health in 2020). A broad incumbent comparable to Intervacc's commercial ambition across species, though at much larger scale.

10Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

One of the largest veterinary biologics manufacturers in the world after the Merial acquisition. Develops and markets vaccines for swine, cattle, equine, and companion animals, making it a directly comparable vaccine R&D and commercial platform to Intervacc's pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intervacc

Animal Health Vaccinesintervacc.se

Intervacc AB is a Swedish animal health biotech developing recombinant fusion protein vaccines, led by its flagship equine strangles vaccine Strangvac® (approved in 16+ European markets) and the pipeline-stage Piggivac® pig vaccine. It serves equine veterinarians and owners across Europe via direct sales (Nordvacc) and Dechra distribution, and is pursuing US regulatory entry.

What Intervacc does

Intervacc AB (publ) is a Swedish biotechnology company listed on Nasdaq First North Growth Market (ticker: IVACC) that develops vaccines based on recombinant fusion protein technology for animal health applications. The company's core technology platform originated from research at Karolinska Institutet and the Swedish University of Agricultural Sciences (SLU), generating broad immune responses by targeting multiple virulence pathways of complex bacterial pathogens. Its flagship commercial product, Strangvac®, is a recombinant subunit vaccine against equine strangles (Streptococcus equi) approved in the EU, UK, Iceland, Norway, and Liechtenstein, providing over 90% protection following booster dose and uniquely offering DIVA (Differentiating Infected from Vaccinated Animals) capability that enables continued disease surveillance. The pipeline includes Piggivac® (INV274), a pig vaccine against Streptococcus suis that became the first globally to demonstrate statistically significant protection against serotypes ST1 and ST16 via maternal immunity, and INV412, a mastitis vaccine candidate for dairy cattle.

The company operates a hybrid distribution model: direct sales through its wholly-owned Nordvacc Läkemedel subsidiary (which has sold more than 200 million vaccine doses and holds distribution rights to 25 products across 8 Scandinavian and Baltic countries) for Scandinavia, and an exclusive distribution agreement with Dechra Pharmaceuticals PLC covering the rest of Europe (extended through April 2028). 2025 net sales were SEK 20.087 million, up 70% year-over-year, and the company is pursuing US regulatory approval with clinical safety studies initiated in December 2025. Beyond Strangvac and Piggivac, Intervacc operates Mybac-Vettech Laboratoriet for clinical microbiological analyses and is funded through a mix of equity (including a SEK 193 million rights issue in February 2025 that brought HealthCap IX Investments AB as a ~26% shareholder), EU grants (Eurostars-2/3), and Swedish innovation agency (Vinnova) grants.

Revenue is generated primarily from vaccine product sales (one-time purchase model through veterinary channels), with strategic positioning that emphasizes antimicrobial resistance reduction, scientific engagement via Key Opinion Leader networks, and awareness campaigns such as Strangles Awareness Week. The company is led by CEO Carl-Johan Dalsgaard (appointed February 2026, previously AstraZeneca) with Andrew Waller as CSO, Jan Persson as CFO, and Anna-Carin Lagerlöf as Director of Sales & Marketing, supported by Board Chair Emil Billbäck (appointed May 2026).

Intervacc firmographics

Firmographics
Name
Intervacc
Legal name
Intervacc AB (publ)
Website
https://intervacc.se
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Intervacc AB is a Swedish animal health biotech developing recombinant fusion protein vaccines, led by its flagship equine strangles vaccine Strangvac® (approved in 16+ European markets) and the pipeline-stage Piggivac® pig vaccine. It serves equine veterinarians and owners across Europe via direct sales (Nordvacc) and Dechra distribution, and is pursuing US regulatory entry.
Ownership category
akta.pro rank

Intervacc industry classification

Industry
Product category
Animal Health Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAIAEAH
Veterinary Vaccines

Keywords

  • Animal health vaccines
  • Recombinant protein vaccines
  • Veterinary pharmaceuticals
  • Equine strangles vaccine
  • Livestock vaccine development

Where Intervacc is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Intervacc business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Vaccine Product Sales: Revenue generated from sales of Strangvac vaccine for horses, sold directly in Scandinavia and through distribution partner Dechra across Europe. Net sales of SEK 20,087 thousand in 2025, up 70% from SEK 11,787 thousand in 2024.
  2. Distribution Rights and Sales: Nordvacc subsidiary sells vaccines and pharmaceuticals across Scandinavia and Baltic countries with distribution rights to 25 products in 8 countries.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Intervacc product offering

Product offering

Core offering

Intervacc develops and commercializes vaccines based on recombinant fusion proteins for animal health, with flagship product Strangvac® protecting horses against strangles (Streptococcus equi) and pipeline product Piggivac® targeting Streptococcus suis in pigs. The company sells Strangvac directly in Scandinavia and through Dechra Pharmaceuticals across Europe, while expanding its vaccine pipeline to address mastitis in dairy cattle.

Product overview

Intervacc is a Swedish animal health group developing vaccines based on recombinant protein fusion technology for animals. The company's core product portfolio includes Strangvac®, an approved equine strangles vaccine registered in 16 European markets; Piggivac®, a pig vaccine against Streptococcus suis in advanced development; and two additional vaccine candidates (INV274 and INV412). Through subsidiaries Nordvacc Läkemedel (sales/distribution) and Mybac-Vettech Laboratoriet (analyses), Intervacc combines in-house vaccine development with established commercial infrastructure across European markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Strangvac® A recombinant fusion protein vaccine against equine strangles (caused by Streptococcus equi), approved for sale and marketing in the EU, UK, Iceland, Norway, and Liechtenstein. Administered intramuscularly, it provides over 90% protection following booster dose and is the only strangles vaccine that permits diagnosis of exposed or infected horses.
  • Piggivac® A subunit vaccine against Streptococcus suis infections in pigs, based on Intervacc's recombinant fusion protein platform. Administered to pregnant sows intramuscularly, transferring maternal immunity to piglets. Demonstrated statistically significant protection against virulent serotypes ST1 (serotype 2) and ST16 (serotype 9). No approved S. suis vaccines currently exist for pigs.
  • Nordvacc Läkemedel (Distribution Services) A wholly-owned subsidiary of Intervacc operating as a sales and distribution organization with over 30 years of experience, having sold more than 200 million vaccine doses on the European animal health market. Handles distribution of Intervacc's products in Scandinavia and holds distribution rights to multiple products across 8 countries.
  • Mybac-Vettech Laboratoriet (Microbiological Analyses) A subsidiary of Nordvacc performing clinical microbiological analyses, supporting diagnostic and analytical service capabilities.

Quantifiable outcome

  • Over 90% protection following booster vaccination against strangles
  • +3 more outcomes

Companies that use Intervacc

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Intervacc technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Intervacc partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Moredun ScientificcoreStrategic or Co-development Partner · 19 March 2026Contract research organization specializing in animal health in Edinburgh, UK. Collaborating on Streptococcus suis vaccine (INV274/Piggivac) development including challenge studies and pivotal registration studies. Project co-funded by Eurostars 3 program.
  • Dechra Pharmaceuticals PLCcoreChannel Partner/ Reseller/ Distributor · 13 October 2025Five-year distribution agreement (original April 2021, extended by 2 years from April 2026) for Strangvac vaccine in Europe excluding Scandinavia, Iceland, and Baltic countries. Dechra has launched Strangvac in 14 countries including UK, France, Germany, Spain, Portugal, Ireland, Poland, Slovenia, and Italy.
  • Testa CentercoreStrategic or Co-development Partner · 17 August 2023Collaboration with Testa Center in Uppsala, Sweden for scale-up manufacturing of Streptococcus suis vaccine component. Project involves optimizing biopharmaceutical production processes with Vinnova funding of 800,000 SEK.
  • Swedish University of Agricultural Sciences (SLU)coreStrategic or Co-development Partner · 11 June 2019Multi-year contract for development of innovative animal health vaccines using recombinant proteins. Research collaboration provides foundation for Intervacc's vaccine platform technology.
  • 3P BiopharmaceuticalscoreTechnology or Integration · 9 July 2018Manufacturing partner in Pamplona, Spain for large-scale commercial production of drug substances in Strangvac vaccine. Technology transfer and validation batch production completed for registration.
  • Praxis Pharmaceuticals (LIOF-Pharma)coreTechnology or Integration · 9 July 2018Provider of final formulation, vial filling, packaging, and final release of finished Strangvac product in Spain.
  • Nordvacc Läkemedel ABcoreChannel Partner/ Reseller/ Distributor · 24 March 2014Wholly-owned subsidiary acquired in 2014 providing established distribution network in Scandinavia and Baltic countries. Has sold more than 150 million vaccine doses and holds distribution rights to 25 products in 8 countries. Also owns Mybac-Vettech performing clinical microbiological analyses.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Intervacc competitors and assessment

Company assessment

Broad incumbents

  • Virbac: Independent French animal health company with a strong vaccine portfolio across livestock, equine, and companion animals, plus a meaningful direct-sales presence in Europe. Closely comparable as a mid-sized independent animal vaccine specialist with European roots and international ambitions.
  • Vetoquinol: Independent French animal health company with a strong veterinary biologics and pharmaceutical portfolio, including equine and livestock products. Comparable as a mid-sized European independent animal health specialist with similar geographic and end-market overlap to Intervacc.
  • Ceva Santé Animale: Major independent global animal health player headquartered in France, especially strong in poultry and swine vaccines. Relevant peer for the swine (Piggivac/INV274) side of Intervacc's portfolio and as a benchmark for independent vaccine R&D organizations competing against Big Pharma incumbents.
  • Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company (acquired by EQT in 2025) with strong European and North American equine/small animal footprint. Dechra is Intervacc's distribution partner for Strangvac in Europe and is directly comparable as a specialty vet pharma commercial channel.
  • Phibro Animal Health: Animal health and nutrition company with a meaningful vaccine and anti-infective business serving livestock and poultry. Comparable as a public pure-play animal health company whose stock-based valuation benchmark is helpful in sizing Intervacc's potential enterprise value trajectory.
  • Merck Animal Health (MSD Animal Health): The animal health division of Merck/MSD, offering vaccines, anti-infectives, and parasiticides globally. Operates the broadest portfolio of licensed veterinary biological products across species and is a key competitor and benchmark for any animal vaccine developer targeting livestock or equine markets.
  • Zoetis: World's largest pure-play animal health company, offering a broad portfolio of vaccines, parasiticides, and diagnostics across livestock and companion animals. Comparable as a manufacturer of veterinary biologics, including equine and livestock vaccines, with established global commercial scale that dwarfs Intervacc's current footprint.
  • Elanco Animal Health: Global pure-play animal health company with significant vaccine franchises in livestock and companion animals (acquired Bayer Animal Health in 2020). A broad incumbent comparable to Intervacc's commercial ambition across species, though at much larger scale.
  • Boehringer Ingelheim Animal Health: One of the largest veterinary biologics manufacturers in the world after the Merial acquisition. Develops and markets vaccines for swine, cattle, equine, and companion animals, making it a directly comparable vaccine R&D and commercial platform to Intervacc's pipeline.

Emerging players

  • IDT Biologika: German veterinary biologics contract manufacturer and vaccine developer with strong expertise in bacterial vaccines across species. Comparable as a specialized European veterinary biologics platform — relevant for both competitive technology benchmarking and as a potential manufacturing counterpart for Intervacc-type recombinant subunit products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Intervacc social profiles

Digital presence

Intervacc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intervacc leadership team

Management profile

Number of profiles

Profiles7 records

Intervacc subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Intervacc funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intervacc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intervacc

What does Intervacc do?

Intervacc develops and commercializes vaccines based on recombinant fusion proteins for animal health, with flagship product Strangvac® protecting horses against strangles (Streptococcus equi) and pipeline product Piggivac® targeting Streptococcus suis in pigs. The company sells Strangvac directly in Scandinavia and through Dechra Pharmaceuticals across Europe, while expanding its vaccine pipeline to address mastitis in dairy cattle.

Is Intervacc a public or private company?

Intervacc is a public company. It is classified as public and is currently operating.

When was Intervacc founded?

Intervacc was founded in 2014. It employs 11 to 50 people.

Where is Intervacc based?

Intervacc is headquartered in Stockholm, Sweden, in the Europe region.

How does Intervacc make money?

Two revenue lines are on record. Vaccine Product Sales are the primary driver. The others are distribution Rights and Sales.

Who are Intervacc's main competitors?

Broad incumbents on record are Virbac, Vetoquinol, Ceva Santé Animale, Dechra Pharmaceuticals, Phibro Animal Health, Merck Animal Health (MSD Animal Health), Zoetis, Elanco Animal Health and Boehringer Ingelheim Animal Health. IDT Biologika is listed as an emerging player.

Does Intervacc have an API?

No public API is recorded for Intervacc.

What industry is Intervacc in?

Intervacc's product category is Animal Health Vaccines. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comNew UK-wide strangles alert scheme launched todayIntervacc AB launched a UK-wide strangles alert scheme developed by Cambridge's EIDS team with JData. The scheme follows a surge in diagnoses, with 937 reported in two years across 83 regions, averaging 9 per week. It aims to help vets and stakeholders implement enhanced control measures.Dagens industriIntervaccs förlust ökarIntervacc reported a third-quarter 2026 operating loss of 27.2 million Swedish kronor, up from 15.0 million in the prior year. The company sells the Strangvac vaccine against the horse disease quark.news.cision.comReal-world Strangvac data shows nearly 100% protectionIntervacc announced that after 100,000 doses of Strangvac were sold in the EU and UK, only 3 confirmed S. equi infections occurred in vaccinated horses, a 0.006% incidence. The data shows nearly 100% protection, validating the vaccine's recombinant technology.news.cision.comInterim report January – June 2026Intervacc reported an operating loss of 42.8 million SEK for the first half of 2026, driven by a 63% revenue decline in Europe outside Sweden despite a 54% increase in its domestic market. The company is intensifying marketing efforts with partner Dechra and has submitted an application to the European Medicines Agency to extend Strangvac's immunity duration from two to twelve months.news.cision.comIntervacc submits Type II variation to EMA seeking 12-month duration of immunity for StrangvacIntervacc submitted a Type II variation to the EMA for Strangvac, seeking to extend the stated duration of immunity to 12 months. The application is supported by data showing protective antibody levels persist for 12 months after primary vaccination. If approved, revaccination could be coordinated with routine influenza vaccination.YahooDiscover 3 European Penny Stocks With Market Caps Under €40MA Simply Wall St screener article profiles two Swedish penny stocks as potential investment opportunities amid European market challenges from geopolitical tensions and rising energy costs. Alpcot Holding AB operates a digital personal finance platform with a market cap of SEK222.53 million and has recently become profitable with forecasted earnings growth of 61.85% per year, while Intervacc AB is a pre-revenue veterinary vaccine developer with a market cap of SEK408.29 million that recently appointed Emil Billbäck as Chair and received vaccine approval in Iceland.news.cision.comEmil Billbäck appointed new Chair of the Board of IntervaccEmil Billbäck was elected new Chair of Intervacc's Board at the Annual General Meeting, succeeding Håkan Björklund, who remains a non-executive Director. Billbäck will focus on the US approval and launch of Strangvac and advancing Piggivac. The appointment aligns with the company's growth and scaling phase.news.cision.comInternational Awareness Initiative Against StranglesStrangles Awareness Week runs May 4-10, with Intervacc leading an Edinburgh conference on prevention guidelines. The campaign, coordinated by SVA and HästSverige, aims to reduce strangles spread in equine operations. Intervacc's Strangvac vaccine is approved in multiple EU and UK countries.news.cision.comIntervacc publishes the 2025 Annual ReportIntervacc AB published its 2025 Annual Report on its website, with an English unaudited translation available. The animal health group's vaccines are based on research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The report was submitted for publication on April 14, 2026.news.cision.comIntervacc announces breakthrough protection against Streptococcus suis infection in pigletsSwedish biotech company Intervacc announced that its vaccine against Streptococcus suis infection in pigs showed breakthrough protection in piglets through maternal immunity transferred from vaccinated pregnant sows. The vaccine demonstrated statistically significant protection (p=0.017) against two virulent serotypes (ST1 and ST16) in separate challenge studies, marking the first time any company has shown such protection, while there are currently no approved S. suis vaccines available for pigs. Intervacc will continue advancing the vaccine toward GMP manufacturing and pivotal clinical studies, with potential to reduce antibiotic use and improve pig farming profitability given the estimated EUR 250 million annual cost of the disease in Europe alone.